Aijing Shang

4.2k total citations · 1 hit paper
34 papers, 2.9k citations indexed

About

Aijing Shang is a scholar working on Oncology, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, Aijing Shang has authored 34 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Surgery and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Aijing Shang's work include Colorectal Cancer Treatments and Studies (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Complement system in diseases (4 papers). Aijing Shang is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Complement system in diseases (4 papers). Aijing Shang collaborates with scholars based in Switzerland, United Kingdom and United States. Aijing Shang's co-authors include Matthias Egger, Linda Nartey, Peter Jüni, Jonathan A C Sterne, Malcolm J. Moore, Sven Trelle, Eric Van Cutsem, Karin Huwiler-Müntener, Daniel Pewsner and Martin Feller and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Aijing Shang

29 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

2009 504 citations Eric Van Cutsem, Aijing Shang et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Aijing Shang

Since Specialization

Citations

This map shows the geographic impact of Aijing Shang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aijing Shang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aijing Shang more than expected).

Fields of papers citing papers by Aijing Shang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aijing Shang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aijing Shang. The network helps show where Aijing Shang may publish in the future.

Co-authorship network of co-authors of Aijing Shang

This figure shows the co-authorship network connecting the top 25 collaborators of Aijing Shang. A scholar is included among the top collaborators of Aijing Shang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aijing Shang. Aijing Shang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting Zfp36 to combat cardiac hypertrophy: Insights into ferroptosis pathways 2025 ·Clinical and Translational Medicine ·Mingyu Zhang, Xiaoxiang Guan, Zheng Dong, (unknown), (unknown), (unknown), Aijing Shang, Yaru Liu, Xiaofei Guo, Bowen Zhang, Bo Zhang, (unknown), (unknown), (unknown), Yuan Jiang, Zhimin Du, Chaoqian Xu	4
2	First documented cases of envenomations in mainland China by Ovophis species (mountain pitvipers): Severe coagulopathy and variable antivenom response in two patients from Yunnan Province 2025 ·Toxicon ·(unknown), Yong Tang, Aijing Shang, Tao You, Bryan G. Fry	0
3	Association between admission Braden Skin Score and delirium in surgical intensive care patients: an analysis of the MIMIC-IV database 2025 ·Frontiers in Neurology ·(unknown), Aijing Shang, (unknown)	0
4	Clinical Profile and Long-Term Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in a Real-World Setting: High Frequency of Anemia Despite Decreased Intravascular Hemolysis 2021 ·Blood ·(unknown), Ferras Alashkar, (unknown), Richard Ofori‐Asenso, (unknown), (unknown), (unknown), Aijing Shang, (unknown)	1
5	Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry 2020 ·Blood ·(unknown), Federico Germini, Man‐Chiu Poon, Arun Keepanasseril, Quazi Ibrahim, Aijing Shang, Francis Nissen, Oliver Meier, Cami S. Sima, Davide Matino, Alfonso Iorio	1
6	Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre 2019 ·Blood ·John Radford, (unknown), Felipe A. Castro, Anshuman Chaturvedi, (unknown), Adam Gibb, Andy Surinach, Kim Linton, Aijing Shang, Michael Wenger	5
7	Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer 2017 ·International Journal of Gynecological Cancer ·Virginia M. Rosen, (unknown), Mary McCormack, Angélica Nogueira‐Rodrigues, André Deeke Sasse, Veronica C. Munk, Aijing Shang	65
8	GetReal in network meta‐analysis: a review of the methodology 2016 ·Research Synthesis Methods ·Orestis Efthimiou, Thomas P. A. Debray, Gert van Valkenhoef, Sven Trelle, (unknown), Karel G.M. Moons, Johannes B. Reitsma, Aijing Shang, Georgia Salanti, (unknown)	268
9	Indirect Treatment Comparisons Of Obinutuzumab (Ga101) Plus Chlorambucil (Clb) Versus Bendamustine And Versus Ofatumumab Plus Clb In Patients With Chronic Lymphocytic Leukemia 2014 ·Value in Health ·Tim Waterboer, (unknown), Aijing Shang, Ursula Becker, (unknown)	2
10	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial 2012 ·The Lancet Oncology ·Aimery de Gramont, Eric Van Cutsem, Hans‐Joachim Schmoll, Josep Tabernero, Stephen Clarke, Malcolm J. Moore, David Cunningham, Thomas H. Cartwright, J. Randolph Hecht, Fernando Rivera, Seock‐Ah Im, G. Bodoky, Ramón Salazar, Frédérique Maindrault‐Gœbel, Einat Shacham‐Shmueli, Emilio Bajetta, Martina Makrutzki, Aijing Shang, Thierry André, Paulo M. Hoff	354
11	AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. 2011 ·Journal of Clinical Oncology ·Armand de Gramont, Eric Van Cutsem, Josep Tabernero, Malcolm J. Moore, David Cunningham, Fernando Rivera, Seock‐Ah Im, Martina Makrutzki, Aijing Shang, Paulo M. Hoff	58
12	Long‐Term Antibiotic Treatment for Crohn's Disease: Systematic Review and Meta‐Analysis of Placebo‐Controlled Trials 2010 ·Clinical Infectious Diseases ·Martin Feller, Karin Huwiler, Alain Schoepfer, Aijing Shang, Hansjakob Furrer, Matthias Egger	81
13	An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary 2008 ·Journal of Clinical Epidemiology ·Roger Harbord, Penny Whiting, Jonathan A C Sterne, Matthias Egger, Jonathan J Deeks, Aijing Shang, Lucas M. Bachmann	177
14	Effectiveness of chlamydia screening: systematic review 2008 ·International Journal of Epidemiology ·Nicola Low, Nicole Bender, Linda Nartey, Aijing Shang, Judith Stephenson	98
15	Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis 2007 ·The Lancet Infectious Diseases ·Martin Feller, Karin Huwiler, Roger Stephan, Ekkehardt Altpeter, Aijing Shang, Hansjakob Furrer, Gaby E. Pfyffer, Thomas Jemmi, A. Baumgärtner, Matthias Egger	400
16	Matched-pair study showed higher quality of placebo-controlled trials in Western phytotherapy than conventional medicine 2007 ·Journal of Clinical Epidemiology ·Linda Nartey, Karin Huwiler-Müntener, Aijing Shang, (unknown), Peter Jüni, Matthias Egger	15
17	Improved effectiveness of partner notification for patients with sexually transmitted infections: systematic review 2007 ·BMJ ·Sven Trelle, Aijing Shang, Linda Nartey, Jackie Cassell, Nicola Low	152
18	Hylan versus hyaluronic acid for osteoarthritis of the knee: A systematic review and meta‐analysis 2007 ·Arthritis Care & Research ·Stephan Reichenbach, (unknown), Anne WS Rutjes, Aijing Shang, Elizabeth A. King, Paul Dieppe, Peter Jüni, Sven Trelle	135
19	Placebo-controlled trials of Chinese herbal medicine and conventional medicine comparative study 2007 ·International Journal of Epidemiology ·Aijing Shang, (unknown), Linda Nartey, Peter Jüni, Matthias Egger	35
20	Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy 2005 ·The Lancet ·Aijing Shang, Karin Huwiler-Müntener, Linda Nartey, Peter Jüni, (unknown), Jonathan A C Sterne, Daniel Pewsner, Matthias Egger	488

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact